Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-01-11
2011-01-11
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
07868141
ABSTRACT:
This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 5202238 (1993-04-01), Fell, Jr. et al.
patent: 5204244 (1993-04-01), Fell et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5874299 (1999-02-01), Lonberg et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 0 307 434 (1993-09-01), None
patent: WO 87/00533 (1987-11-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 92/12227 (1992-07-01), None
patent: WO 92/22645 (1992-12-01), None
patent: WO 94/11026 (1994-05-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 95/05468 (1995-02-01), None
patent: WO 95/12673 (1995-05-01), None
patent: WO 95/21915 (1995-08-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 99/15200 (1999-04-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 01/14424 (2001-03-01), None
patent: WO 01/25492 (2001-04-01), None
patent: WO 01/94586 (2001-12-01), None
Hezareh, M., et al.,Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1, Journal of Virology, 2001, pp. 12161-12168, vol. 75(24).
Nohara. C., et al.,Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells, Journal of Immunology, 2001, pp. 2108-2115, vol. 166(3).
Wang. Q., et al.,Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signaling: enhancement of IgG production of B cells and promotion of maturation of DCs, Tissue Antigens, 2004, pp. 566-574, vol. 64(5).
Akiba, H., et al., “CD28-Independent Costimulation of T Cells by OX40 Ligand and CD70 on Activated B Cells,”J Immunol. Jun. 15, 1999; 162(12):7058-66.
Arestides, R.S., et al., “Costimulatory Molecule OX40L is Critical for Both Th1 and Th2 Responses in Allergic Inflammation,”Eur. J. Immunol. Oct. 2002; 32(10):2874-80.
Bertram, E.M., et al., “Role of T Cell Costimulation in Anti-Viral Immunity,”Semin Immunol. Jun. 2004; 16(3):185-96. Review.
Burgess, J.K., et. al., “Detection and Characterization of OX40 Ligand Expression in Human Airway Smooth Mucsle Cells: A Possible Role in Asthma?,”J Allergy Clin Immunol. Apr. 2004 113(4):683-9.
Chen, A.I.,. et al., “Ox40-Ligand Has a Critical Costimulatory Role in Dendritic Cell: T Cell Interactions,”Immunity. Dec. 1999; 11(6):689-98.
Gramaglia, I., et al., “The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion,”J Immunol. Sep. 15, 2000;165(6):3043-50.
Grosenbach, D.W., et al., “A Recombinant Vector Expressing Transgenes for Four T-Cell Costimulatory Molecules (OX40L, B7-1, ICAM-1, LFA-3) Induces Sustained CD4+ and CD8+ T-Cell Activation, Protection from Apoptosis, and Enhanced Cytokine Production,” CellImmunol. Mar. 2003; 222(1):45-57.
Gruss, H.J. “Molecular, Structural, and Biological Chararcteristics of the Tumor Necrosis Factor Ligand Superfamily,” Int. J Clin. Lab Res 1996; 26(3): 143-59.
Hoshino, A., et al., “Critical Role for OX40 Ligand in the Development of Pathogenic Th2 Cells in a Murine Model of Asthma,”Eur J Immunol. Apr. 2003; 33(4):861-9.
Ishii, et al.; “OX40 (CD134) and OX40 Ligand Interaction Plays an Adjuvant Role during In Vivo Th2 Responses,” Eur J Immunol. Sep. 2003; 33(9)2372-81.
Ito, T., et al., “Plasmacytoid Dentritic Cells Regulate Th Cell Responses through OX40 Ligand and Type I IFNs1,”J Immunol. Apr. 1, 2004; 172(7):4253-9.
Kato, H., et al., Essential Role of OX40L on B Cells in Persistent Alloantibody Production Following Repeated Alloimmunizations,J Clin Immunol. May 2004; 24(3):237-48.
Linton, P.J., et al., “Costimulation via OX40L Expressed by B Cells Sufficient to Determine the Extent of Primary CD4 Cell Expansion and Th2 Cytokine Secretion In Vivo,”J. Exp Med. Apr. 7, 2003; 197(7):875-83. Epub Mar. 31, 2003.
Murata, K., et al., “Constitutive OX40/OX40 Ligand Interaction Induces Autoimmune-Like Diseases,”J. Immunol. Oct. 15, 2002; 169(8):4628-36.
Murata, K., et al., “Impairment of Antigen-Presenting Cell Function in Mice Lacking Expression of OX40 Ligand,”J. Exp Med. Jan. 17, 2000; 191(2):365-74.
Ndhlovu, L.C., et al., “Critical Involvement of OX40 Ligand Signals in the T Cell Priming Events During Experimental Autoimmune Encephalomyelitis,”J Immunol. Sep. 1, 2001; 167(5):2991-9.
Nohara, C., et al., “Amelioration of Experimental Autoimmune Encephalomyelitis with Anti-OX40 Ligand Monoclonal Antibody: A Critical Role for OX40 Ligand in Migration, But Not Development, of Pathogenic T Cells,”J Immunol. Feb. 1, 2001; 166(3):2108-15.
Obermeier, F., et al., “OX40/OX40L Interaction Induces the Expression of CXCR5 and Contributes to Chronic Colitis induced by Dextran Sulfate Sodium in Mice,”Eur J Immunol. Dec. 2003; 33(12):3265-74.
Ohshima, Y., et al., “Expression and Function of OX40 Ligand on Human Dendritic Cells,”J. Immunol. Oct. 15, 1997; 159(8):3838-48.
Salek-Ardakani, S., et al., “OX40 (CD134) Controls Memory T Helper 2 Cells that Drive Lung Inflammation,”J Exp Med. Jul. 21, 2003; 198(2):315-24. Epub Jul. 14, 2003.
Sato, T., et al., “Consequences of OX40-OX40 Ligand interactions in Langerhans Cell Function: Enhanced Contact Hypersensitivity Responses in OX40L-Transgenic Mice,”Eur J Immunol. Nov. 2002; 32(11):3326-35.
Straw, A.D., et al., “CD154 Plays a Central Role in Regulating Dendritic Cell Activation During Infections That Induce Th1 and Th2 Responses,”J. Immunol. Jan. 15, 2003; 170(2):727-34.
Stuber, E., et al., “The Expression of OX40 in Immunologically Mediated Diseases of the Gastrointestinal Tract (Celiac Disease, Crohn's Disease, Ulcerative Colitis),”Eur J Clin Invest. Jul. 2000; 30(7):594-9.
Stuber, E., et al., “The T Cell-B Cell Interaction via OX40-OX40L is Necessary for the T Cell-Dependent Humoral Immune Response,”J. Exp. Med. Mar. 1, 1996;183(3):979-89.
Takeda, I., et al., “Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells,”J Immunol. Mar. 15, 2004; 172(6):3580-9.
Totsuka, T., et al., “Therapeutic Effect of Anti-OX40L and Anti-TNF-alpha MAbs in a Murine Model of Chronic Colitis,”Am J Physiol Gastrointest Liver Physiol. Apr. 2003; 284(4):G595-603. Epub Jan. 10, 2003.
Ukyo, N., et al., Costimulation through OX40 is Crucial for Induction of an Alloreactive Human T-Cell Response,Immunology. Jan. 2003; 109(2):226-31.
Yoshioka, T., et al., “Contribution of OX40/OX40 Ligand Interation to the Pathogenesis of Rheumatoid Arthritis,”Eur J Immunol. Oct. 2000; 30(10):2815-23.
Akiba, H. et al., “Identification of Rat OX40 Ligand by Molecular Cloning,”Biochem. Biophys. Res. Commun. 251 (1998) 131-136.
Akiba, H. et al., “Critical Contribution of OX40 Ligand to T Helper Cell Type 2 Differentiation in Experimental Leishmaniasis,”J. Exp. M
Endl Joseph
Eugui Elsie M.
Fuentes Maria Elena
Graus Yvo
Labrijn Aran Frank
Hall Robert C.
Ouspenski Ilia
Roche Palo Alto LLC
LandOfFree
Anti-OX40L antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-OX40L antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-OX40L antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725083